000950 重藥控股
按盤價 
5.760 +0.420 (+7.865%)
5.760 +0.420 (+7.865%) | 2024/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 39,779,228 | -2.30% | 80,119,107 | 67,829,010 | 62,520,755 | 45,219,571 | |
| 減：營業總成本 | 39,271,948 | -1.60% | 79,031,580 | 66,608,402 | 61,148,245 | 44,064,665 | |
| 其中:營業成本 | 36,688,624 | -1.64% | 73,810,393 | 62,008,780 | 56,782,329 | 40,985,178 | |
| 財務費用 | 545,106 | -15.12% | 1,302,028 | 1,094,235 | 1,087,649 | 701,598 | |
| 資產減值損失 | (90) | -97.99% | (27,756) | (39,943) | (12,883) | (8,912) | |
| 公允價值變動收益 | 8,906 | 1,010.11% | 16,162 | 2,318 | 126,883 | 17,452 | |
| 投資收益 | 163,900 | 6.72% | 301,548 | 293,349 | 302,690 | 287,978 | |
| 其中：對聯營企業和合營企業的投資收益 | 163,351 | 12.23% | 291,454 | 286,195 | 279,408 | 284,769 | |
| 營業利潤 | 442,526 | -40.78% | 1,007,095 | 1,435,011 | 1,560,927 | 1,371,385 | |
| 利潤總額 | 446,092 | -40.97% | 1,008,541 | 1,472,490 | 1,580,286 | 1,374,461 | |
| 減：所得稅費用 | 103,387 | -18.37% | 236,042 | 309,496 | 289,613 | 227,070 | |
| 淨利潤 | 342,705 | -45.52% | 772,499 | 1,162,995 | 1,290,673 | 1,147,391 | |
| 減：非控股權益 | 104,617 | -9.36% | 117,542 | 210,719 | 285,229 | 263,046 | |
| 股東淨利潤 | 238,089 | -53.65% | 654,957 | 952,276 | 1,005,444 | 884,344 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.140 | -51.72% | 0.380 | 0.550 | 0.580 | 0.510 | |
| 每股派息 (元) * | -- | -- | 0.050 | 0.060 | 0.105 | -- | |
| 每股淨資產 (元) * | 6.594 | 2.55% | 6.507 | 6.110 | 5.633 | 5.113 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 30/09/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
